Sign in
TerminatedPhase 1

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Key facts

Who runs it
Taipei Medical University Shuang Ho Hospital
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
9 people enrolled
Started
20 Sept 2022
Ended
26 Mar 2024
Type of study
Interventional, 2 groups
Treatments tested
  • chidamide
  • celecoxib
Record updated
20 December 2024
Why it stopped
The overall profile does not support development for metastatic colorectal cancer

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • The patient is 20-year-old or older on the day that consent is provided
  • With histologically or cytologically proven metastatic colorectal adenocarcinoma
  • Have measurable lesions according to RECIST v1.1
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 to 2
  • Adequate organ function as defined below:; White blood cells (WBC) ≥3,000/μL ii. Absolute neutrophil count ≥1,500/μL iii. Platelets ≥1 x 105/μL iv. Hemoglobin ≥9.0 g/dL v. Total bilirubin ≤1.5 x the upper limit of normal (ULN) vi. AST(SGOT)/ALT(SGPT) ≤3 x ULN (or ≤5 x ULN if liver metastases are present) vii. Serum creatinine ≤1.5 x ULN
  • Patients who had received or were intolerant of at least 2 front-line systemic treatments. In addition, patients have failed or refused all available standard treatment, or were intolerant of such treatments. For K-ras wild type tumor, anti-EGFR therapy must have been done. For K-ras mutant tumor, antiangiogenic therapy must have been done
  • Able to take oral medication
  • With a life expectancy of at least 3 months
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test
  • Patients in reproductive age must be willing to use adequate contraception (refer to Section 8.4.2 of the protocol for adequate contraception methods) during the study and 3 months after the end of the study
  • Ability to understand and the willingness to provide a written informed consent document

Who cannot take part

  • Able to take oral medication
  • Has had prior chemotherapy, targeted small molecule therapy, radiation therapy, or any NSAID within 2 weeks prior to the first dose of study medication or who has not recovered from adverse events to CTCAE v5.0 Grade 1 due to a previously administered agent
  • With active infection [suffered from active infection of bacteria, virus, fungi, mycobacteria, parasites, or other infections (excluding nail bed fungal infections), or require intravenous antibiotic therapy, or antiviral therapy, or hospitalization due to any significant infection events within 4 weeks], or persistent fever within 14 days prior to study entry
  • Had major surgery <6 weeks prior to study entry
  • Is currently participating and receiving study therapy, or has participated in a study of an investigational agent and received study therapy or used an investigation device within 4 weeks of the first dose of study medication
  • With known central nervous system (CNS) metastases, a history of CNS metastases or leptomeningeal diseases
  • With known hypersensitivity towards chidamide, celecoxib, sulfonamides, aspirin, NSAIDs, or any other agents used in the study, including the excipient in the study agent; or with history of asthma, urticarial, or other allergic-type reactions after taking aspirin or other NSAIDs
  • With the size of fluid area detected by cardiac ultrasonography in cavum pericardium ≥ 10 mm
  • With history of organ transplantation
  • With known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
  • With autoimmune disorders or history of organ transplantation who require immunosuppressive therapy
  • Has known psychiatric disorder, mental deficiency, or substance abuse disorder that would limit compliance with study requirements
  • Adequate organ function as defined below:; White blood cells (WBC) ≥3,000/μL ii. Absolute neutrophil count ≥1,500/μL iii. Platelets ≥1 x 105/μL iv. Hemoglobin ≥9.0 g/dL v. Total bilirubin ≤1.5 x the upper limit of normal (ULN) vi. AST(SGOT)/ALT(SGPT) ≤3 x ULN (or ≤5 x ULN if liver metastases are present) vii. Serum creatinine ≤1.5 x ULN
  • Patients who had received or were intolerant of at least 2 front-line systemic treatments. In addition, patients have failed or refused all available standard treatment, or were intolerant of such treatments. For K-ras wild type tumor, anti-EGFR therapy must have been done. For K-ras mutant tumor, antiangiogenic therapy must have been done
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test
  • With severe systemic disease, such as renal disease (serum creatinine >1.5 x ULN), liver disease (AST/ALT >3 x ULN, AST/ALT >5 x ULN if metastatic liver disease were known), active gastrointestinal hemorrhage or increased risks of gastrointestinal bleeding, uncontrolled diabetes, or uncontrolled hypertension
  • With uncontrolled or significant cardiovascular diseases, including:; Symptomatic congestive heart failure within 6 months prior to screening, or left ventricular ejection fraction <50% prior to screening ii. Myocardial infarction within 12 months prior to screening iii. Severe or unstable angina within 6 months prior to screening iv. History of any significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, or TdP) v. History of significant QT interval prolongation, or corrected QT interval (QTc) >450 ms prior to screening vi. History of cerebrovascular accident vii. Symptomatic coronary heart disease requiring treatment with agents
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might interfere the results of the trial or is not in the best interest of the subject to participate, in the opinion of the investigator
  • Patients in reproductive age must be willing to use adequate contraception (refer to Section 8.4.2 of the protocol for adequate contraception methods) during the study and 3 months after the end of the study
  • (I) Inclusion criteria:
  • The patient is 20-year-old or older on the day that consent is provided
  • With histologically or cytologically proven metastatic colorectal adenocarcinoma
  • Have measurable lesions according to RECIST v1.1
  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 to 2
  • With a life expectancy of at least 3 months
  • Ability to understand and the willingness to provide a written informed consent document; (II) Exclusion criteria:
  • Has clinical significant gastrointestinal abnormality, e.g., unable to swallow, chronic diarrhea, ileus, or bowel obstruction, which would interfere the ingestion, transportation, or absorption of oral agents
  • Pregnant or lactating female

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.

The 2 groups in the trial

  • chidamide (20 mg) BIW in combination with celecoxib (CC)Treatment being tested

    Chidamide: The dosing schedule is four/six tablets (20 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days. Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast. A treatment cycle is defined as a period of 4 weeks (28 days)

    Treatment: chidamide and celecoxib

  • chidamide(30 mg) BIW in combination with celecoxib (CC)Treatment being tested

    Chidamide: The dosing schedule is four/six tablets (30 mg) BIW, taken at 30 min after breakfast. The interval between two doses in each week should not be less than 3 days. Celecoxib: The dosing schedule is one capsule (200 mg) daily taken at 30 min after breakfast. A treatment cycle is defined as a period of 4 weeks (28 days)

    Treatment: chidamide and celecoxib

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase Ib Study of Chidamide in Combination With Celecoxib in Patients With Metastatic Colorectal Cancer Who Had Progression or Were Intolerant of at Least Two Lines of Systemic Therapies (CCmCC)
Record updated
20 December 2024